ArthralgiaPhase 3NCT01573442
Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment
A Phase 3 study testing testosterone in people with Arthralgia and Breast Cancer, run by Alliance for Clinical Trials in Oncology at 529 sites in 2 countries.
Trial summary
This randomized phase III trial studies testosterone to see how well it works compared to placebo in treating postmenopausal patients with arthralgia (joint pain) caused by anastrozole or letrozole. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Arthralgia, Breast Cancer, Hot Flashes
- What is being tested?
- testosterone
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 227 participants
- Where
- 529 sitesin 2 countries
- Study dates
- 10 Sep 2013to 1 Sep 2019
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age ≥ 18 years
- Receiving anastrozole (1mg) or letrozole (2.5 mg) orally once a day, for ≥ 21 days prior to registration and plan to continue it throughout the duration of study
- Body Mass Index (BMI) between 18 and 35 kg/m^2
- Women who have undergone a total mastectomy or breast conserving surgery for primary breast cancer +/-chemo, +/-radiotherapy.
- Must have BOTH ER and PR receptor-positive tumors and BOTH must be ≥26% positive. Alternatively, if ER and PR are determined by Allred score, the score needs to be 5 or higher
- Women who are postmenopausal by surgery, radiotherapy or presence of natural amenorrhea ≥ 12 months
Show all 18Show fewer
- ≥ 5/10 arthralgia (in hands, wrist, knees, or hips) while being treated with anastrozole or letrozole which is felt by the patient to be caused by their aromatase inhibitor as defined in the protocol. Note: Patients may, or may not, be taking non-opioid analgesics
- Ability to complete questionnaire(s) by themselves or with assistance
- ECOG Performance Status (PS) 0, 1 or 2
- Willing to provide informed written consent
- Willing to return to an Alliance enrolling institution for follow-up
- Willing to provide blood samples for correlative research purposes
- Laboratory values prior to registration as defined in the protocol:
- Creatinine ≤1.5 x ULN
- Hemoglobin > 11 g/dL
- WBC > 3.0
- Platelet Count > 100,000
- SGOT (AST) ≤ 1.5 x ULN
Who cannot join
- Presence of residual or recurrent cancer (locally or metastatic)
- Diabetes mellitus or glucose intolerance, defined as a fasting glucose >125 mg/dL
- History of coronary artery disease (angina or myocardial infarction)
- Patients on hormone replacement therapy (HRT) ≤ 4 weeks prior to registration. This includes the use of vaginal estrogen therapy.
- Known hypersensitivity to any component of testosterone.
- Prolonged systemic corticosteroid treatment, except for topical applications (e.g. for rash), inhaled sprays (e.g. for obstructive airway diseases), eye drops or local insertion (e.g. intra-articular). Note: Short duration (< 2 weeks) of systemic corticosteroids is allowed (e.g. for chronic obstructive pulmonary disease) but not within 30 days prior to registration.
Show all 11Show fewer
- Receiving any other investigational agent
- History of a deep venous thrombosis or a thromboembolism
- Concurrent use of the aromatase inhibitor exemestane, as it is structurally similar to an androgen
- Concurrent radiation therapy or chemotherapy
- Current or planned use of cyclosporine, anticoagulants, oxphenbutazone, insulin, oral or injectable vitamin D doses over 4,000IU/day, or tamoxifen
Trial locations and contacts
529 sites in 2 countries.
301 sites in 2 countries
United States300 sites
Avera Cancer Institute-Aberdeen
Aberdeen, South Dakota, 57401
Providence Regional Cancer System-Aberdeen
Aberdeen, Washington, 98520
Bixby Medical Center
Adrian, Michigan, 49221
Hickman Cancer Center
Adrian, Michigan, 49221
Akron General Medical Center
Akron, Ohio, 44307
Mary Greeley Medical Center
Ames, Iowa, 50010
McFarland Clinic PC-William R Bliss Cancer Center
Ames, Iowa, 50010
Community Hospital of Anaconda
Anaconda, Montana, 59711
Cancer Care Center at Island Hospital
Anacortes, Washington, 98221
Anchorage Associates in Radiation Medicine
Anchorage, Alaska, 98508
Anchorage Radiation Therapy Center
Anchorage, Alaska, 99504
Alaska Breast Care and Surgery LLC
Anchorage, Alaska, 99508
Alaska Oncology and Hematology LLC
Anchorage, Alaska, 99508
Alaska Women's Cancer Care
Anchorage, Alaska, 99508
Anchorage Oncology Centre
Anchorage, Alaska, 99508
Katmai Oncology Group
Anchorage, Alaska, 99508
Providence Alaska Medical Center
Anchorage, Alaska, 99508
ThedaCare Regional Cancer Center
Appleton, Wisconsin, 54911
University Cancer and Blood Center LLC
Athens, Georgia, 30607
Northside Hospital
Atlanta, Georgia, 30342
Sutter Auburn Faith Hospital
Auburn, California, 95602
Sutter Cancer Centers Radiation Oncology Services-Auburn
Auburn, California, 95603
Augusta University Medical Center
Augusta, Georgia, 30912
Rocky Mountain Cancer Centers-Aurora
Aurora, Colorado, 80012
The Medical Center of Aurora
Aurora, Colorado, 80012
Rush - Copley Medical Center
Aurora, Illinois, 60504
Saint Louis Cancer and Breast Institute-Ballwin
Ballwin, Missouri, 63011
Flaget Memorial Hospital
Bardstown, Kentucky, 40004
Ochsner Health Center-Summa
Baton Rouge, Louisiana, 70809
Franciscan Saint Francis Health-Beech Grove
Beech Grove, Indiana, 46107
PeaceHealth Saint Joseph Medical Center
Bellingham, Washington, 98225
Gaston Hematology and Oncology Associates-Belmont
Belmont, North Carolina, 28012
Sanford Clinic North-Bemidgi
Bemidji, Minnesota, 56601
Saint Charles Health System
Bend, Oregon, 97701
Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California, 94704
Constantinou, Costas L MD (UIA Investigator)
Bettendorf, Iowa, 52722
University of Iowa Healthcare Cancer Services Quad Cities
Bettendorf, Iowa, 52722
Billings Clinic Cancer Center
Billings, Montana, 59101
Saint Vincent Healthcare
Billings, Montana, 59101
Montana Cancer Consortium NCORP
Billings, Montana, 59102
Saint Vincent Frontier Cancer Center
Billings, Montana, 59102
Sanford Bismarck Medical Center
Bismarck, North Dakota, 58501
Saint Joseph Medical Center
Bloomington, Illinois, 61701
Illinois CancerCare-Bloomington
Bloomington, Illinois, 61704
Saint Luke's Mountain States Tumor Institute
Boise, Idaho, 83712
Central Care Cancer Center - Bolivar
Bolivar, Missouri, 65613
Parkland Health Center-Bonne Terre
Bonne Terre, Missouri, 63628
McFarland Clinic PC-Boone
Boone, Iowa, 50036
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114
Boulder Community Hospital
Boulder, Colorado, 80301
Rocky Mountain Cancer Centers-Boulder
Boulder, Colorado, 80304
Toledo Clinic Cancer Centers-Bowling Green
Bowling Green, Ohio, 43402
Bozeman Deaconess Hospital
Bozeman, Montana, 59715
Harrison HealthPartners Hematology and Oncology-Bremerton
Bremerton, Washington, 98310
Harrison Medical Center
Bremerton, Washington, 98310
Wellmont Bristol Regional Medical Center
Bristol, Tennessee, 37620
Wellmont Medical Associates Oncology and Hematology-Bristol
Bristol, Tennessee, 37620
Saint Joseph Regional Cancer Center
Bryan, Texas, 77802
Providence Saint Joseph Medical Center/Disney Family Cancer Center
Burbank, California, 91505
Highline Medical Center-Main Campus
Burien, Washington, 98166
Mills-Peninsula Medical Center
Burlingame, California, 94010
Cone Health Cancer Center at Alamance Regional
Burlington, North Carolina, 27215
Aurora Cancer Care-Southern Lakes VLCC
Burlington, Wisconsin, 53105
Saint James Community Hospital and Cancer Treatment Center
Butte, Montana, 59701
Cooper Hospital University Medical Center
Camden, New Jersey, 08103
Sutter Cancer Centers Radiation Oncology Services-Cameron Park
Cameron Park, California, 95682
Illinois CancerCare-Canton
Canton, Illinois, 61520
Saint Francis Medical Center
Cape Girardeau, Missouri, 63703
Southeast Cancer Center
Cape Girardeau, Missouri, 63703
Memorial Hospital of Carbondale
Carbondale, Illinois, 62902
SIH Cancer Institute
Carterville, Illinois, 62918
Illinois CancerCare-Carthage
Carthage, Illinois, 62321
Rocky Mountain Oncology
Casper, Wyoming, 82609
Eden Hospital Medical Center
Castro Valley, California, 94546
Mercy Hospital
Cedar Rapids, Iowa, 52403
Oncology Associates at Mercy Medical Center
Cedar Rapids, Iowa, 52403
Dayton Physicians LLC-Miami Valley South
Centerville, Ohio, 45459
Miami Valley Hospital South
Centerville, Ohio, 45459
Centralia Oncology Clinic
Centralia, Illinois, 62801
Providence Regional Cancer System-Centralia
Centralia, Washington, 98531
Cancer Center of Kansas - Chanute
Chanute, Kansas, 66720
Roper Hospital
Charleston, South Carolina, 29401
Charleston Hematology Oncology Associates-Roper
Charleston, South Carolina, 29403
Lowcountry Hematology Oncology PA-North Charleston
Charleston, South Carolina, 29406
Bon Secours Saint Francis Hospital
Charleston, South Carolina, 29414
Charleston Hematology Oncology Associates PA-Saint Francis
Charleston, South Carolina, 29414
Lowcountry Hematology Oncology PA-West Ashley
Charleston, South Carolina, 29414
Novant Health Presbyterian Medical Center
Charlotte, North Carolina, 28204
Carolina Surgical Clinic of Charlotte PA
Charlotte, North Carolina, 28207
Oncology Specialists of Charlotte
Charlotte, North Carolina, 28207
Southern Oncology Specialists-Charlotte
Charlotte, North Carolina, 28262
Memorial Hospital
Chattanooga, Tennessee, 37404
Cheyenne Regional Medical Center-West
Cheyenne, Wyoming, 82001
Weiss Memorial Hospital
Chicago, Illinois, 60640
Oncology Hematology Care Inc-Eden Park
Cincinnati, Ohio, 45202
Oncology Hematology Care Inc-Mercy West
Cincinnati, Ohio, 45211
University of Cincinnati/Barrett Cancer Center
Cincinnati, Ohio, 45219
Good Samaritan Hospital - Cincinnati
Cincinnati, Ohio, 45220
Oncology Hematology Care Inc - Anderson
Cincinnati, Ohio, 45230
Oncology Hematology Care Inc-Kenwood
Cincinnati, Ohio, 45236
Bethesda North Hospital
Cincinnati, Ohio, 45242
Oncology Hematology Care Inc-Blue Ash
Cincinnati, Ohio, 45242
TriHealth Cancer Institute-Westside
Cincinnati, Ohio, 45247
TriHealth Cancer Institute-Anderson
Cincinnati, Ohio, 45255
Clackamas Radiation Oncology Center
Clackamas, Oregon, 97015
Providence Oncology and Hematology Care Southeast
Clackamas, Oregon, 97015
Southeastern Medical Oncology Center-Clinton
Clinton, North Carolina, 28328
Medical Oncology and Hematology Associates-West Des Moines
Clive, Iowa, 50325
Mercy Cancer Center-West Lakes
Clive, Iowa, 50325
Big Horn Basin Cancer Center
Cody, Wyoming, 82414
Billings Clinic-Cody
Cody, Wyoming, 82414
Kootenai Medical Center
Coeur d'Alene, Idaho, 83814
Penrose-Saint Francis Healthcare
Colorado Springs, Colorado, 80907
Rocky Mountain Cancer Centers-Penrose
Colorado Springs, Colorado, 80907
John B Amos Cancer Center
Columbus, Georgia, 31904
New Hampshire Oncology Hematology PA-Concord
Concord, New Hampshire, 03301
Bay Area Hospital
Coos Bay, Oregon, 97420
Commonwealth Cancer Center-Corbin
Corbin, Kentucky, 40701
Alegent Health Mercy Hospital
Council Bluffs, Iowa, 51503
Greater Regional Medical Center
Creston, Iowa, 50801
Oncology Hematology Care Inc-Crestview
Crestview Hills, Kentucky, 41017
Mass General/North Shore Cancer Center
Danvers, Massachusetts, 01923
Carle on Vermilion
Danville, Illinois, 61832
Sutter Davis Hospital
Davis, California, 95616
Grandview Hospital
Dayton, Ohio, 45405
Good Samaritan Hospital - Dayton
Dayton, Ohio, 45406
Miami Valley Hospital
Dayton, Ohio, 45409
Dayton Physicians LLC-Samaritan North
Dayton, Ohio, 45415
Samaritan North Health Center
Dayton, Ohio, 45415
Dayton NCI Community Oncology Research Program
Dayton, Ohio, 45420
Dekalb Medical Center
Decatur, Georgia, 30033
Cancer Care Specialists of Central Illinois
Decatur, Illinois, 62526
Decatur Memorial Hospital
Decatur, Illinois, 62526
Porter Adventist Hospital
Denver, Colorado, 80210
Colorado Blood Cancer Institute
Denver, Colorado, 80218
Presbyterian - Saint Lukes Medical Center - Health One
Denver, Colorado, 80218
Rocky Mountain Cancer Centers-Midtown
Denver, Colorado, 80218
SCL Health Saint Joseph Hospital
Denver, Colorado, 80218
Rocky Mountain Cancer Centers-Rose
Denver, Colorado, 80220
Rose Medical Center
Denver, Colorado, 80220
Colorado Cancer Research Program NCORP
Denver, Colorado, 80222
Iowa-Wide Oncology Research Coalition NCORP
Des Moines, Iowa, 50309
Medical Oncology and Hematology Associates-Laurel
Des Moines, Iowa, 50314
Mercy Medical Center - Des Moines
Des Moines, Iowa, 50314
Cancer Center of Kansas - Dodge City
Dodge City, Kansas, 67801
Epic Care-Dublin
Dublin, California, 94568
Mercy Medical Center
Durango, Colorado, 81301
Southwest Oncology PC
Durango, Colorado, 81301
Greenville Health System Cancer Institute-Easley
Easley, South Carolina, 29640
Marshfield Clinic Cancer Center - Eau Claire
Eau Claire, Wisconsin, 54701
Marshfield Clinic Cancer Center at Sacred Heart
Eau Claire, Wisconsin, 54701
Saint Elizabeth Medical Center South
Edgewood, Kentucky, 41017
Swedish Medical Center-Edmonds
Edmonds, Washington, 98026
Carle Physician Group-Effingham
Effingham, Illinois, 62401
Crossroads Cancer Center
Effingham, Illinois, 62401
Cancer Center of Kansas - El Dorado
El Dorado, Kansas, 67042
Hematology Oncology Center Incorporated
Elyria, Ohio, 44035
Mercy Cancer Center-Elyria
Elyria, Ohio, 44035
Bay Area Breast Surgeons Inc
Emeryville, California, 94608
Epic Care Partners in Cancer Care
Emeryville, California, 94608
Comprehensive Cancer Care and Research Institute of Colorado LLC
Englewood, Colorado, 80113
Swedish Medical Center
Englewood, Colorado, 80113
Englewood Hospital and Medical Center
Englewood, New Jersey, 07631
Saint Elizabeth Hospital
Enumclaw, Washington, 98022
Green Bay Oncology - Escanaba
Escanaba, Michigan, 49829
Illinois CancerCare-Eureka
Eureka, Illinois, 61530
Providence Regional Cancer Partnership
Everett, Washington, 98201
IMG Hematology Oncology 8501
Fairfax, Virginia, 22031
Inova Fair Oaks Hospital
Fairfax, Virginia, 22033
Oncology Hematology Care Inc-Healthplex
Fairfield, Ohio, 45014
Roger Maris Cancer Center
Fargo, North Dakota, 58122
Sanford Broadway Medical Center
Fargo, North Dakota, 58122
Sanford Clinic North-Fargo
Fargo, North Dakota, 58122
Saint Francis Hospital
Federal Way, Washington, 98003
Armes Family Cancer Center
Findlay, Ohio, 45840
Blanchard Valley Hospital
Findlay, Ohio, 45840
Orion Cancer Care
Findlay, Ohio, 45840
Aurora Health Center-Fond du Lac
Fond du Lac, Wisconsin, 54937
McFarland Clinic PC-Trinity Cancer Center
Fort Dodge, Iowa, 50501
Cancer Center of Kansas - Fort Scott
Fort Scott, Kansas, 66701
Saint Elizabeth Fort Thomas
Fort Thomas, Kentucky, 41075
Atrium Medical Center-Middletown Regional Hospital
Franklin, Ohio, 45005-1066
Dayton Physicians LLC-Atrium
Franklin, Ohio, 45005
Fredericksburg Oncology Inc
Fredericksburg, Virginia, 22401
Palo Alto Medical Foundation-Fremont
Fremont, California, 94538
Washington Hospital
Fremont, California, 94538
Saint Luke's Mountain States Tumor Institute - Fruitland
Fruitland, Idaho, 83619
Illinois CancerCare-Galesburg
Galesburg, Illinois, 61401
Western Illinois Cancer Treatment Center
Galesburg, Illinois, 61401
CaroMont Regional Medical Center
Gastonia, North Carolina, 28054
Gaston Hematology and Oncology Associates
Gastonia, North Carolina, 28054
Northwestern Medicine Cancer Center Delnor
Geneva, Illinois, 60134
Aurora Health Care Germantown Health Center
Germantown, Wisconsin, 53022
Glens Falls Hospital
Glens Falls, New York, 12801
Mountain Blue Cancer Care Center
Golden, Colorado, 80401
Southeastern Medical Oncology Center-Goldsboro
Goldsboro, North Carolina, 27534
Wayne Memorial Hospital
Goldsboro, North Carolina, 27534
Aurora Cancer Care-Grafton
Grafton, Wisconsin, 53024
Altru Cancer Center
Grand Forks, North Dakota, 58201
CHI Health Saint Francis
Grand Island, Nebraska, 68803
Benefis Healthcare- Sletten Cancer Institute
Great Falls, Montana, 59405
Great Falls Clinic
Great Falls, Montana, 59405
North Colorado Medical Center
Greeley, Colorado, 80631
Green Bay Oncology at Saint Vincent Hospital
Green Bay, Wisconsin, 54301-3526
Saint Vincent Hospital Cancer Center Green Bay
Green Bay, Wisconsin, 54301
Green Bay Oncology Limited at Saint Mary's Hospital
Green Bay, Wisconsin, 54303
Saint Vincent Hospital Cancer Center at Saint Mary's
Green Bay, Wisconsin, 54303
Aurora BayCare Medical Center
Green Bay, Wisconsin, 54311
Dayton Physicians LLC-Wayne
Greenville, Ohio, 45331
Wayne Hospital
Greenville, Ohio, 45331
Greenville Health System Cancer Institute-Andrews
Greenville, South Carolina, 29601
Greenville Health System Cancer Institute-Butternut
Greenville, South Carolina, 29605
Greenville Health System Cancer Institute-Faris
Greenville, South Carolina, 29605
Greenville Memorial Hospital
Greenville, South Carolina, 29605
Greenville Health System Cancer Institute-Eastside
Greenville, South Carolina, 29615
Rocky Mountain Cancer Centers-Greenwood Village
Greenwood Village, Colorado, 80111
Greenville Health System Cancer Institute-Greer
Greer, South Carolina, 29650
Ingalls Memorial Hospital
Harvey, Illinois, 60426
Saint Peter's Community Hospital
Helena, Montana, 59601
Cancer and Blood Specialists-Henderson
Henderson, Nevada, 89052
Comprehensive Cancer Centers of Nevada - Henderson
Henderson, Nevada, 89052
Las Vegas Cancer Center-Henderson
Henderson, Nevada, 89052
21st Century Oncology-Henderson
Henderson, Nevada, 89074
Comprehensive Cancer Centers of Nevada-Southeast Henderson
Henderson, Nevada, 89074
Pulmonary Medicine Center of Chattanooga-Hixson
Hixson, Tennessee, 37343
New Hampshire Oncology Hematology PA-Hooksett
Hooksett, New Hampshire, 03106
CHI Saint Vincent Cancer Center Hot Springs
Hot Springs, Arkansas, 71913
Lake Norman Hematology Oncology Specialists-Huntersville
Huntersville, North Carolina, 28078
Southern Oncology Specialists-Huntersville
Huntersville, North Carolina, 28078
Cancer Center of Kansas-Independence
Independence, Kansas, 67301
Indiana University/Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, 46202
Franciscan Health Indianapolis
Indianapolis, Indiana, 46237
Green Bay Oncology - Iron Mountain
Iron Mountain, Michigan, 49801
Swedish Cancer Institute-Issaquah
Issaquah, Washington, 98029
Jackson-Madison County General Hospital
Jackson, Tennessee, 38301
Southeastern Medical Oncology Center-Jacksonville
Jacksonville, North Carolina, 28546
McFarland Clinic PC-Jefferson
Jefferson, Iowa, 50129
Capital Region Medical Center-Goldschmidt Cancer Center
Jefferson City, Missouri, 65109
Wellmont Medical Associates Oncology and Hematology-Johnson City
Johnson City, Tennessee, 37604
Freeman Health System
Joplin, Missouri, 64804
Mercy Hospital Joplin
Joplin, Missouri, 64804
Kalispell Medical Oncology
Kalispell, Montana, 59901
Kalispell Regional Medical Center
Kalispell, Montana, 59901
Heartland Hematology and Oncology
Kearney, Nebraska, 68845
CHI Health Good Samaritan
Kearney, Nebraska, 68847
Kadlec Clinic Hematology and Oncology
Kennewick, Washington, 99336
Aurora Cancer Care-Kenosha South
Kenosha, Wisconsin, 53142
Greater Dayton Cancer Center
Kettering, Ohio, 45409
Kettering Medical Center
Kettering, Ohio, 45429
Illinois CancerCare-Kewanee Clinic
Kewanee, Illinois, 61443
Cancer Center of Kansas-Kingman
Kingman, Kansas, 67068
Wellmont Holston Valley Hospital and Medical Center
Kingsport, Tennessee, 37660
Wellmont Medical Associates Oncology and Hematology-Kingsport
Kingsport, Tennessee, 37660
Kinston Medical Specialists PA
Kinston, North Carolina, 28501
University of Tennessee - Knoxville
Knoxville, Tennessee, 37920
Gundersen Lutheran Medical Center
La Crosse, Wisconsin, 54601
Mayo Clinic Health System-Franciscan Healthcare
La Crosse, Wisconsin, 54601
AMITA Health Adventist Medical Center
La Grange, Illinois, 60525
Providence Regional Cancer System-Lacey
Lacey, Washington, 98503
LRGHealthcare-Lakes Region General Hospital
Laconia, New Hampshire, 03246
Lakeland Regional Health Hollis Cancer Center
Lakeland, Florida, 33805
Rocky Mountain Cancer Centers-Lakewood
Lakewood, Colorado, 80228
Saint Anthony Hospital
Lakewood, Colorado, 80228
Saint Clare Hospital
Lakewood, Washington, 98499
Doctor's Hospital of Laredo
Laredo, Texas, 78041
University Medical Center of Southern Nevada
Las Vegas, Nevada, 89102
Cancer and Blood Specialists-Shadow
Las Vegas, Nevada, 89106
Nevada Cancer Research Foundation CCOP
Las Vegas, Nevada, 89106
Radiation Oncology Centers of Nevada Central
Las Vegas, Nevada, 89106
21st Century Oncology
Las Vegas, Nevada, 89109
HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway
Las Vegas, Nevada, 89109
HealthCare Partners Medical Group Oncology/Hematology-San Martin
Las Vegas, Nevada, 89113
Radiation Oncology Centers of Nevada Southeast
Las Vegas, Nevada, 89119
Cancer Therapy and Integrative Medicine
Las Vegas, Nevada, 89121
21st Century Oncology-Vegas Tenaya
Las Vegas, Nevada, 89128
Cancer and Blood Specialists-Tenaya
Las Vegas, Nevada, 89128
Comprehensive Cancer Centers of Nevada - Northwest
Las Vegas, Nevada, 89128
HealthCare Partners Medical Group Oncology/Hematology-Tenaya
Las Vegas, Nevada, 89128
Comprehensive Cancer Centers of Nevada-Summerlin
Las Vegas, Nevada, 89144
Las Vegas Cancer Center-Medical Center
Las Vegas, Nevada, 89148-2405
21st Century Oncology-Fort Apache
Las Vegas, Nevada, 89148
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, 89148
Nevada Cancer Specialists-Fort Apache
Las Vegas, Nevada, 89148
HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills
Las Vegas, Nevada, 89149
Comprehensive Cancer Centers of Nevada - Central Valley
Las Vegas, Nevada, 89169
Lawrence Memorial Hospital
Lawrence, Kansas, 66044
Beebe Medical Center
Lewes, Delaware, 19958
Central Maine Medical Center
Lewiston, Maine, 04240
Saint Mary's Regional Medical Center
Lewiston, Maine, 04240
Saint Joseph Radiation Oncology Resource Center
Lexington, Kentucky, 40504
Saint Joseph Hospital East
Lexington, Kentucky, 40509
University of Kentucky/Markey Cancer Center
Lexington, Kentucky, 40536
Cancer Center of Kansas-Liberal
Liberal, Kansas, 67905
Lima Memorial Hospital
Lima, Ohio, 45804
Saint Elizabeth Regional Medical Center
Lincoln, Nebraska, 68510
Rocky Mountain Cancer Centers-Littleton
Littleton, Colorado, 80120
Littleton Adventist Hospital
Littleton, Colorado, 80122
The Dana-Farber Cancer Institute at Londonderry
Londonderry, New Hampshire, 03053
Rocky Mountain Cancer Centers-Sky Ridge
Lone Tree, Colorado, 80124
Sky Ridge Medical Center
Lone Tree, Colorado, 80124
About this study
Official title: Randomized Double-Blind Placebo Controlled Study of Testosterone in the Adjuvant Treatment of Postmenopausal Women With Aromatase Inhibitor Induced Arthralgias
This randomized phase III trial studies testosterone to see how well it works compared to placebo in treating postmenopausal patients with arthralgia (joint pain) caused by anastrozole or letrozole. Testosterone may help relieve moderate or severe arthralgia associated with the use of aromatase inhibitors, such as anastrozole or letrozole.
Read the detailed description
This is a randomized, placebo-controlled, phase III trial evaluating subcutaneous testosterone for the alleviation of aromatase inhibitor induced arthralgia. A parallel group design will be utilized for this two-arm study: subcutaneous testosterone vs. placebo. Patients are stratified according to baseline pain score (5-6 vs. 7-10) and age (< 50 vs. 50-60 vs. > 60). The primary objective is to determine whether testosterone will reduce AI-induced arthralgia and associated joint symptoms. The secondary objective is to explore whether testosterone will have an acceptable safety and tolerability profile, with particular reference to androgenic adverse events including acne, hirsutism, and alopecia.
Patients are followed up to six months as defined in the protocol.
- Being tested
- testosterone, placebo
- Keywords
- hot flashes, musculoskeletal complications, sexual dysfunction, estrogen receptor-positive breast cancer, progesterone receptor-positive breast cancer, arthralgia, stage IA breast cancer, stage IB breast cancer, stage II breast cancer, stage IIIA breast cancer, stage IIIB breast cancer, stage IIIC breast cancer
- Medical subject headings
- Arthralgia, Breast Neoplasms, Hot Flashes, Sexual Dysfunction, Physiological
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
testosteroneDrug
10.4 mg
placeboOther
| Study group | Role | What they receive |
|---|---|---|
| Arm I | Experimental | Patients receive testosterone (0.264mL) topical application daily for six months. Receives: Drug: testosterone |
| Arm II | Placebo comparator | Patients receive placebo (0.264mL) topical application daily for six months. Receives: Other: placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Item #3 (Average) of the Brief Pain Inventory (BPI) Average Pain From Baseline to Month 3
The average change in Brief Pain Inventory (BPI) Average Pain scores between baseline and month 3 using Wilcoxon test are reported for each arm below. The BPI scales range from 0 to 10 with 0 meaning no pain and 10 meaning pain as bad as you can imagine.
Measured: From baseline to 3 months
Improvement in BPI Average Pain From Baseline to Month 3
"2. Was there an improvement in BPI Average Pain from baseline to month 3?"
Measured: Up to 3 months
Change in BPI Average Change From Baseline Pain Score to Month Six Average Pain Score
Change in BPI Average Change from Baseline Pain Score to Month Six Average Pain Score. The BPI scales range from 0 to 10 with 0 meaning no pain and 10 meaning pain as bad as you can imagine.
Measured: Baseline and 6 months
Change in BPI Average Pain From Baseline to Month 1-6
Change in BPI Average Pain from baseline to month 1-6. The BPI scales range from 0 to 10 with 0 meaning no pain and 10 meaning pain as bad as you can imagine.
Measured: Baseline and months 1-6
Secondary outcomes (12)
Number of Participants With Grade 3 Or Higher Adverse Events Considered At Least Possibly Related to Treatment
The maximum grade for each type of toxicity will be recorded for each patient, and frequency tables will be reviewed to determine toxicity patterns within patient groups. In addition, we will review all adverse event data that is graded as 3, 4, or 5 and classified as either "unrelated" or "unlikely to be related" to study treatment in the event of an actual relationship developing. The overall toxicity rates (percentages) for grade 3 or higher adverse events considered at least possibly related to treatment are reported below.
Measured: Up to 6 months
Number of Patients Who Reported Alopecia Using CTCAE 4.0
The number of patients who reported alopecia using CTCAE 4.0 is reported below for each arm.
Measured: Up to 6 months
Number of Patients Who Reported Acne Using CTCAE 4.0
The number of patients who reported acne using CTCAE 4.0 is reported below for each arm.
Measured: Up to 6 months
Number of Patients Who Reported Hirsutism Using CTCAE 4.0
The number of patients who reported hirsutism using CTCAE 4.0 is reported below for each arm by grade.
Measured: Up to 6 months
Change in Hot Flash Frequency From Baseline to Week 8
Change in hot flash frequency from baseline to week 8. Hot flash frequency is a count of the number of hot flashes per day and is a number from 0 to infinity. Higher values are worse.
Measured: baseline and week 8
The Change of Libido From Baseline to Month 3 as Measured by the MENQOL
Change in how bothered are you by decreased sex drive from baseline to month 3. This is assessed using one question off of the MENQOL (Menopause-Specific Quality of Life) questionnaire. The question asks "How bothered are you by a decrease in your sexual drive". This is collected on a scale ranging from 0=Not at all bothered to 6=Extremely bothered, with higher values being worse.
Measured: baseline and month 3
The Change of Menopause Specific Quality of Life From Baseline to Month 3 as Measured by MENQOL "How Bothered Are You by Hot Flashes"
The change of menopause specific quality of life from baseline to month 3 as measured by MENQOL "how bothered are you by Hot Flashes". This is one question from the MENQOL (Menopause-Specific Quality of Life) questionnaire. The question asks "How bothered are you by hot flashes or flushes". This is collected on a scale ranging from 0=Not at all bothered t 6=Extremely bothered, with higher values being worse.
Measured: baseline and month 3
Change in BPI Worst Pain From Baseline to Month 3
Change in BPI Worst Pain from baseline to month 3. The BPI scales range from 0 to 10 with 0 meaning no pain and 10 meaning pain as bad as you can imagine.
Measured: baseline and month 3
Change in BPI Least Pain From Baseline to Month 3
Change in BPI Least Pain from baseline to month 3. The BPI scales range from 0 to 10 with 0 meaning no pain and 10 meaning pain as bad as you can imagine.
Measured: baseline and month 3
Change in BPI Pain Right Now From Baseline to Month 3
Change in BPI Pain right now from baseline to month 3. The BPI scales range from 0 to 10 with 0 meaning no pain and 10 meaning pain as bad as you can imagine.
Measured: baseline and month 3
Change in Average Joint Stiffness From Baseline to Month 3 as Measured by BPI Item #5 (Joint Stiffness)
Change in average joint stiffness from baseline to month 3. The BPI scales range from 0 to 10 with 0 meaning no pain and 10 meaning pain as bad as you can imagine.
Measured: baseline and month 3
The Intrapatient Change in Activity Level (Interference of Activity) for Each Month From Baseline as Measured by Item#6 (Interference) of the BPI-AIA.
The intrapatient change in activity level (interference of activity) for each month from baseline as measured by item#6 (interference) of the BPI-AIA. Change in general activity from baseline to month 3. The BPI scales range from 0 to 10 with 0 meaning no pain and 10 meaning pain as bad as you can imagine.
Measured: baseline and month 3
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Apr 2012 (estimated)
- Study start10 Sep 2013
- Primary completion28 Feb 2018
- Study completion1 Sep 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for ArthralgiaStudies of the same condition, open and under way.
- More trials run by Alliance for Clinical Trials in OncologyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 227 participants (actual)
Sponsor and investigators
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- Charles Loprinzi, MD, Study chair, Mayo Clinic
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01573442
- Sponsor's protocol ID
- A221102
- Other IDs
- CDR0000730083, NCI-2012-00719, U10CA037447, UG1CA189823
- Status last verified
- Jan 2025
- First submitted
- 6 Apr 2012
- Last updated
- 28 Jan 2025
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Publications
Cathcart-Rake E, Novotny P, Leon-Ferre R, Le-Rademacher J, Storrick EM, Adjei AA, Terstriep S, Glaser R, Giuliano A, Mitchell WR, Page S, Austin C, Deming RL, Ferreira MA, Lafky JM, Birrell SN, Loprinzi CL. A randomized, double-blind, placebo-controlled trial of testosterone for treatment of postmenopausal women with aromatase inhibitor-induced arthralgias: Alliance study A221102. Support Care Cancer. 2021 Jan;29(1):387-396. doi: 10.1007/s00520-020-05473-2. Epub 2020 May 6.
PubMed 32372176
Study at a glance
From the registry record, last updated by the sponsor on 28 Jan 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Randomized Double-Blind Placebo Controlled Study of Testosterone in the Adjuvant Treatment of Postmenopausal Women With Aromatase Inhibitor Induced Arthralgias
- ClinicalTrials.gov ID
- NCT01573442
- Acronym / sponsor ID
- A221102
- Keywords
- hot flashes, musculoskeletal complications, sexual dysfunction, estrogen receptor-positive breast cancer, progesterone receptor-positive breast cancer, arthralgia, stage IA breast cancer, stage IB breast cancer
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 227 participants (actual)
- Lead sponsor
- Alliance for Clinical Trials in OncologyUniversity, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Study start
- 10 Sep 2013 (actual)
- Primary completion
- 28 Feb 2018 (actual)
- Study completion
- 1 Sep 2019 (actual)
- First posted
- 9 Apr 2012 (estimated)
- Results
- Posted 5 Jun 2019
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This randomized phase III trial studies testosterone to see how well it works compared to placebo in treating postmenopausal patients with arthralgia (joint pain) caused by anastrozole or letrozole. Testosterone may help relieve moderate or severe arthralgia associated with the use of aromatase inhibitors, such as anastrozole or letrozole.
Detailed description
This is a randomized, placebo-controlled, phase III trial evaluating subcutaneous testosterone for the alleviation of aromatase inhibitor induced arthralgia. A parallel group design will be utilized for this two-arm study: subcutaneous testosterone vs. placebo. Patients are stratified according to baseline pain score (5-6 vs. 7-10) and age (< 50 vs. 50-60 vs. > 60). The primary objective is to determine whether testosterone will reduce AI-induced arthralgia and associated joint symptoms. The secondary objective is to explore whether testosterone will have an acceptable safety and tolerability profile, with particular reference to androgenic adverse events including acne, hirsutism, and alopecia.
Patients are followed up to six months as defined in the protocol.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Arm I | Experimental | Drug: testosteronePatients receive testosterone (0.264mL) topical application daily for six months. |
| Arm II | Placebo comparator | Other: placeboPatients receive placebo (0.264mL) topical application daily for six months. |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (18 listed)
- Age ≥ 18 years
- Receiving anastrozole (1mg) or letrozole (2.5 mg) orally once a day, for ≥ 21 days prior to registration and plan to continue it throughout the duration of study
- Body Mass Index (BMI) between 18 and 35 kg/m^2
- Women who have undergone a total mastectomy or breast conserving surgery for primary breast cancer +/-chemo, +/-radiotherapy.
- Must have BOTH ER and PR receptor-positive tumors and BOTH must be ≥26% positive. Alternatively, if ER and PR are determined by Allred score, the score needs to be 5 or higher
Key exclusion criteria (11 listed)
- Presence of residual or recurrent cancer (locally or metastatic)
- Diabetes mellitus or glucose intolerance, defined as a fasting glucose >125 mg/dL
- History of coronary artery disease (angina or myocardial infarction)
- Patients on hormone replacement therapy (HRT) ≤ 4 weeks prior to registration. This includes the use of vaginal estrogen therapy.
- Known hypersensitivity to any component of testosterone.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| testosterone10.4 mg | Drug | Arm I |
| placebo | Other | Arm II |
Primary outcome
Change in Item #3 (Average) of the Brief Pain Inventory (BPI) Average Pain From Baseline to Month 3
Time frame: From baseline to 3 months
The average change in Brief Pain Inventory (BPI) Average Pain scores between baseline and month 3 using Wilcoxon test are reported for each arm below. The BPI scales range from 0 to 10 with 0 meaning no pain and 10 meaning pain as bad as you can imagine.
Improvement in BPI Average Pain From Baseline to Month 3
Time frame: Up to 3 months
"2. Was there an improvement in BPI Average Pain from baseline to month 3?"
Change in BPI Average Change From Baseline Pain Score to Month Six Average Pain Score
Time frame: Baseline and 6 months
Change in BPI Average Change from Baseline Pain Score to Month Six Average Pain Score. The BPI scales range from 0 to 10 with 0 meaning no pain and 10 meaning pain as bad as you can imagine.
Change in BPI Average Pain From Baseline to Month 1-6
Time frame: Baseline and months 1-6
Change in BPI Average Pain from baseline to month 1-6. The BPI scales range from 0 to 10 with 0 meaning no pain and 10 meaning pain as bad as you can imagine.
12 secondary outcomes
Number of Participants With Grade 3 Or Higher Adverse Events Considered At Least Possibly Related to Treatment
Time frame: Up to 6 months
Number of Patients Who Reported Alopecia Using CTCAE 4.0
Time frame: Up to 6 months
Number of Patients Who Reported Acne Using CTCAE 4.0
Time frame: Up to 6 months
Number of Patients Who Reported Hirsutism Using CTCAE 4.0
Time frame: Up to 6 months
Change in Hot Flash Frequency From Baseline to Week 8
Time frame: baseline and week 8
The Change of Libido From Baseline to Month 3 as Measured by the MENQOL
Time frame: baseline and month 3
The Change of Menopause Specific Quality of Life From Baseline to Month 3 as Measured by MENQOL "How Bothered Are You by Hot Flashes"
Time frame: baseline and month 3
Change in BPI Worst Pain From Baseline to Month 3
Time frame: baseline and month 3
Change in BPI Least Pain From Baseline to Month 3
Time frame: baseline and month 3
Change in BPI Pain Right Now From Baseline to Month 3
Time frame: baseline and month 3
Change in Average Joint Stiffness From Baseline to Month 3 as Measured by BPI Item #5 (Joint Stiffness)
Time frame: baseline and month 3
The Intrapatient Change in Activity Level (Interference of Activity) for Each Month From Baseline as Measured by Item#6 (Interference) of the BPI-AIA.
Time frame: baseline and month 3
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Jan 2025.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 32372176Cathcart-Rake E, Novotny P, Leon-Ferre R, Le-Rademacher J, Storrick EM, Adjei AA, Terstriep S, Glaser R, Giuliano A, Mitchell WR, Page S, Austin C, Deming RL, Ferreira MA, Lafky JM, Birrell SN, Loprinzi CL. A randomized, double-blind, placebo-controlled trial of testosterone for treatment of postmenopausal women with aromatase inhibitor-induced arthralgias: Alliance study A221102. Support Care Cancer. 2021 Jan;29(1):387-396. doi: 10.1007/s00520-020-05473-2. Epub 2020 May 6.
- Clinical trial summary from the National Cancer Institute's PDQ® databaseLink provided by the sponsor.
- Data Available: Select individual patient-level data from this trial can be requested from the NCTN/NCORP Data ArchiveLink provided by the sponsor.
Related trials for Arthralgia
Recruiting
Effects of Cervicothoracic Mobilization in Patients With Supraspinatus Tendinitis
Rotator Cuff Tendonitis
Not yet recruiting
Geriatric Oncology Assessment and Coping Skills Training for Older Women on Aromatase Inhibitor Therapy
Breast Cancer, Hormone Receptor Positive, Aromatase Inhibitor-Associated Arthralgia
Recruiting
Hybrid mHealth and Telerehabilitation vs Conventional Physiotherapy for Subacromial Pain Syndrome
Subacromial Pain Syndrome
Recruiting
Marine Lipids Ease Painful TMD
Temporomandibular Disorder (TMD)
RecruitingPhase 2
Reishi Mushroom Extract for Fatigue and/or Arthralgias/Myalgias in Patients With Breast Cancer on Aromatase Inhibitors
Estrogen Receptor-Positive Breast Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Charles Loprinzi, MD study chair
Mayo Clinic
529 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing testosterone in people with Arthralgia and Breast Cancer, run by Alliance for Clinical Trials in Oncology at 529 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 18 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 529 sites in United States, Puerto Rico. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 5 Jun 2019). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Item #3 (Average) of the Brief Pain Inventory (BPI) Average Pain From Baseline to Month 3 (time frame: From baseline to 3 months). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01573442, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Jan 2025.